Breckenridge Pharma files ANDA for generic of Sanofi's Jevtana
Privately-held US generic drugmaker Breckenridge Pharmaceutical has filed an Abbreviated New Drug Application with the US Food and drug administration, with a Paragraph IV certification for cabazitaxel solution; IV (infusion), a generic version of French pharma major Sanofi’s (Euronext: SAN) cancer drug Jevtana.
On January 14, 2015, Sanofi filed a Paragraph IV law suit against Breckenridge in the US District Court for the District of New Jersey. Breckenridge filed its Paragraph IV ANDA on the first-possible submission date and expects to be entitled to 180-day exclusivity. The ANDA was developed and will be manufactured by Breckenridge's partner, Natco Pharma.
Jevtana is a prescription drug that is indicated to treat prostate cancer. It generated US sales of $120.2 million for the 12-month period ending November 2014, based on industry sales data, quoted by Breckenridge. Globally, Jevtana sales reached 273 million euros ($310 million) in 2014, Sanofi reported earlier this month.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze